About Probable methyltransferase-like protein 24
Probable methyltransferase-like protein 24 (METTL24) is a protein
from Homo sapiens identified by UniProt accession
Q5JXM2, 366 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | Probable methyltransferase-like protein 24 |
| UniProt accession | Q5JXM2 |
| Gene | METTL24 |
| Organism | Homo sapiens |
| Length | 366 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (21)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.37
- mean platelet volume · score 0.33
- platelet count · score 0.17
- platelet component distribution width · score 0.13
- neoplasm · score 0.05
- mean corpuscular hemoglobin concentration · score 0.05
- IRIDA syndrome · score 0.04
- Hemolytic anemia due to red cell pyruvate kinase deficiency · score 0.04
- Rh deficiency syndrome · score 0.03
- congenital dyserythropoietic anemia type 4 · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5JXM2-F1 | alphafold | PREDICTED | 77.91 | — |
Amino-acid sequence (366 residues)
MARERPPGRG CGVLRRCLLG AVLLFGLRLC AELRRAGPGS PTRSAPPGPA WRPPGPHLPP APGQPRGASR RQVTYVRSGR RAPPGGGGSG TPEPGCCAPR GRPRRKGPRW HIDLQPWAGS AQSLDEEAWR FLRYISTTQI ACNHMNTDSL ATDSSPTHKP WSVCLDDRFN LAHQIRNKQC RLYSLGLGSD DTHFEVSMAN NGCEVHRFDP SVKSAHILES QHLWYHRLSI DWRDPHPAVA AQKPHSNTRK LGSILNEFGH HKIDVLKADL ESAEWKVLEN LILEDVLEQI GQLIFEIHLH WPGFEVSGSD SSVVRFWYSL LKELEQKDFR LFHSYKDLSK PQLFLKKDIF NASSCYTLSW VNTRWK
Explore Probable methyltransferase-like protein 24 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets